Skip to main content

AbbVie vs Johnson & Johnson: Revenue, Profit and Business Model

AbbVie had $61.2B of annual revenue in FY2025 and $4.2B of net income. Johnson & Johnson had $94.2B of annual revenue in FY2025 and $26.8B of net income.

Latest financial snapshot

AbbVie

Latest annual revenue
$61.2B (FY2025)
Net income
$4.2B
Net margin
6.9%
Revenue growth
+10.1% a year, FY2016–FY2025

Johnson & Johnson

Latest annual revenue
$94.2B (FY2025)
Net income
$26.8B
Net margin
28.5%
Revenue growth
+3.0% a year, FY2016–FY2025

Financial summary

AbbVie

AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets. AbbVie is a dominant biopharmaceutical company, sustaining a massive market valuation often exceeding $250 billion, heavily driven by its blockbuster immunology and aesthetics portfolios.

Johnson & Johnson

J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026. Johnson & Johnson is a healthcare juggernaut, maintaining a massive market valuation often exceeding $350 billion.

Revenue and profit by year

AbbVie

AbbVie revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$61.2B$4.2B6.9%+8.6%Source
FY2024$56.3B$4.3B7.6%+3.7%Source
FY2023$54.3B$4.9B9.0%-6.4%Source
FY2022$58.1B$11.8B20.4%+3.3%Source
FY2021$56.2B$11.5B20.5%+22.7%Source
FY2020$45.8B$4.6B10.1%+37.7%Source
FY2019$33.3B$7.9B23.7%+1.6%Source
FY2018$32.8B$5.7B17.4%+16.1%Source
FY2017$28.2B$5.3B18.8%+10.1%Source
FY2016$25.6B$6B23.2%—Source
Full AbbVie financials

Johnson & Johnson

Johnson & Johnson revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$94.2B$26.8B28.5%+6.0%Source
FY2024$88.8B$14.1B15.8%+4.3%Source
FY2023$85.2B$35.2B41.3%+6.5%Source
FY2022$80B$17.9B22.4%+1.6%Source
FY2021$78.7B$20.9B26.5%-4.7%Source
FY2020$82.6B$14.7B17.8%+0.6%Source
FY2019$82.1B$15.1B18.4%+0.6%Source
FY2018$81.6B$15.3B18.8%+6.7%Source
FY2017$76.5B$1.3B1.7%+6.3%Source
FY2016$71.9B$16.5B23.0%—Source
Full Johnson & Johnson financials

Where the revenue comes from

AbbVie

  • Immunology Portfolio49.7%

    FY2025 revenue was $30.406 billion, led by Skyrizi, Rinvoq, and Humira.

  • Neuroscience Portfolio17.6%

    FY2025 revenue was $10.767 billion, including Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta.

  • Oncology Portfolio10.9%

    FY2025 revenue was $6.655 billion, including Imbruvica, Venclexta, and Elahere.

  • Aesthetics Portfolio7.9%

    FY2025 revenue was $4.860 billion, including Botox Cosmetic and Juvederm.

  • Other Products and Revenue13.9%

    The remaining FY2025 revenue came from eye care, other specialty products, and other revenue.

Johnson & Johnson

  • Innovative Medicine~64%

    Innovative Medicine generated $60.401 billion in FY2025 sales across oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism.

  • MedTech~36%

    MedTech generated $33.792 billion in FY2025 sales across surgery, orthopaedics, cardiovascular, and vision products.

Business model and strategy

AbbVie

How it makes money

AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Formed in 2013 as a spin-off from Abbott Laboratories, AbbVie built its initial commercial empire around Humira (adalimumab)—historically the world's best-selling biologic medicine.

Growth strategy

AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.

Competitive advantage

AbbVie's durable competitive moat is built upon its world-class commercial execution in immunology, unmatched patent estate design, and the high-margin cash flow engine of the Allergan aesthetics portfolio.

AbbVie business model in full

Johnson & Johnson

How it makes money

Johnson & Johnson is a global healthcare titan that operates through two focused, high-margin divisions following the successful corporate spinoff of its consumer health business (Kenvue): Innovative Medicine and MedTech.

Growth strategy

J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025).

Competitive advantage

Johnson & Johnson's durable competitive moat is built upon its dual-pillar enterprise architecture, unmatched hospital procurement distribution channels, and an elite AAA-rated corporate balance sheet shared with only one other public company globally.

Johnson & Johnson business model in full

Questions about AbbVie vs Johnson & Johnson

Which company has higher revenue — AbbVie Inc. or Johnson & Johnson?

AbbVie Inc. had $61.2B (FY2025), while Johnson & Johnson had $94.2B (FY2025). By latest annual revenue, Johnson & Johnson is the larger business, with AbbVie Inc. showing a smaller revenue base.

What is the market cap of AbbVie Inc. vs Johnson & Johnson?

AbbVie Inc.'s market capitalisation stands at $465.8B, while Johnson & Johnson's is $643.9B. Johnson & Johnson carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to AbbVie Inc..

How does revenue per employee compare for AbbVie Inc. and Johnson & Johnson?

AbbVie Inc. has $1.07M / employee in revenue per employee, while Johnson & Johnson has $669k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do AbbVie Inc. and Johnson & Johnson make money?

AbbVie Inc. and Johnson & Johnson generate revenue in fundamentally different ways. AbbVie Inc.: AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Johnson & Johnson: Johnson & Johnson is a global healthcare titan that operates through two focused, high-margin divisions following the successful corporate spinoff of its consumer health business (Kenvue): Innovative Medicine and MedTech.

Which company is valued higher relative to revenue — AbbVie Inc. or Johnson & Johnson?

On a price-to-sales (P/S) basis, AbbVie Inc. trades at 7.6x P/S and Johnson & Johnson at 6.8x P/S. AbbVie Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Johnson & Johnson. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is AbbVie Inc. bigger than Johnson & Johnson?

By last reported revenue, Johnson & Johnson ($94.2B (FY2025)) is the larger company compared to AbbVie Inc. ($61.2B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Johnson & Johnson overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.